Effects of high-energy ball-milling on injectability and strength of β-tricalcium-phosphate cement

The effect of supplementing the calcium phosphate cement containing poloxamer 407 on cellular activities

Calcium phosphate cement (CPC) is generally used for bone repair and augmentation. Poloxamers are tri-block copolymers that are used as surfactants but have applications in drug and antibiotic delivery. However, their biological effects on bone regeneration systems remain unelucidated. Here, we aimed to understand how supplementing the prototype CPC with poloxamer would impact cellular activity and its function as a bone-grafting material. A novel CPC, modified beta-tricalcium phosphate (mβ-TCP) powder, was developed through a planetary ball-milling process using a beta-tricalcium phosphate (β-TCP). The mβ-TCP dissolves rapidly and accelerates hydroxyapatite precipitation; successfully shortening the cement setting time and enhancing the strength. Furthermore, the addition of poloxamer 407 to mβ-TCP could reduce the risk of leakage from bone defects and improve fracture toughness while maintaining mechanical properties. In this study, the poloxamer addition effects (0.05 and 0.1 g/mL) on the cellular activities of MC3T3-E1 cells cultured in vitro were investigated. The cell viability of mβ-TCP containing poloxamer 407 was similar to that of mβ-TCP. All specimens showed effective cell attachment and healthy polygonal extension of the cytoplasm firmly attached to hydroxyapatite (HA) crystals. Therefore, even with the addition of poloxamer to mβ-TCP, it does not have a negative effect to osteoblast growth. These data demonstrated that the addition of poloxamer 407 to mβ-TCP might be considered a potential therapeutic application for the repair and regeneration of bone defects.

Effects of poloxamer additives on strength, injectability, and shape stability of beta-tricalcium phosphate cement modified using ball-milling

A new CPC was developed in this study using a β-TCP powder mechano-chemically modified by ball-milling. The prototype CPC exhibits excellent fluidity for easy injection into bone defects; however, there is a risk of leakage from the defects immediately after implantation due to its high fluidity. The addition of poloxamer, an inverse thermoresponsive gelling agent, into CPC optimizes the fluidity. At lower temperatures, it forms a sol and maintains good injectability, whereas at the human body temperature, it transforms to a gel, reducing the fluidity and risk of leakage. In this study, the effects of poloxamer addition of 3, 5, and 10 mass% on the injectability, shape stability, and strength of the prototype CPC were evaluated. The calculated injectability of the prototype CPC pastes containing three different poloxamer contents was higher than that of the CPC paste without poloxamer for 15 min at 37 °C. Furthermore, the shape stability immediately after injection of the three CPC pastes with poloxamer was higher than that of the CPC paste without poloxamer. After 1 week of storage at 37 °C, the compressive strength and diametral tensile strength of the CPC compacts containing 10 mass% poloxamer were similar to those of the CPC compact without poloxamer. Additionally, the CPC compacts containing 10 mass% poloxamer exhibited clear plastic deformation after fracture. These results indicate that the addition of poloxamer to the prototype CPC could reduce the risk of leakage from bone defects and improve the fracture toughness with maintaining the injectability and strength.

Magnesium-based bioceramics in orthopedic applications

Magnesium ions are directly involved in numerous biological mechanisms; for example, they play an important part in the regulation of ion channels, DNA stabilization, enzyme activation and stimulation of cell growth and proliferation. This alkaline earth metal has gained great popularity in orthopedic applications in recent years. Magnesium-based bioceramics include a large group of magnesium containing compounds such as oxides, phosphates and silicates, that are involved in orthopedic applications like bone cements, bone scaffolds or implant coatings. This article aims to give a comprehensive review on different magnesium-based bioceramics, e.g. magnesium phosphates (MgO-P₂O₅), calcium magnesium phosphates (CaO-MgO-P₂O₅), and magnesium glasses (SiO₂-MgO) with a strong focus on the chemistry and properties of magnesium phosphate containing cements as the main application form. In addition, the processing of magnesium phosphate minerals into macroporous scaffolds for tissue engineering applications by either using traditional porogens or by additive manufacturing approaches are reflected. Finally, the biological in vitro and in vivo properties of magnesium phosphates for bone regeneration are summarized, which show promising results regarding the application as bone replacement material, but still lack in terms of testing in large animal models, load-bearing application sites and clinical data.

STATEMENT OF SIGNIFICANCE

Though bone substitutes from calcium phosphates have been investigated for a long time, a new trend is visible in the biomaterials sector: magnesium based bioceramics from magnesium phosphates and silicates due to the special biological significance of magnesium ions in enzymatic activation, cell growth and proliferation, etc. In contrast to pure magnesium implants, such formulations do not release hydrogen during degradation. As with calcium based bioceramics, magnesium based bioceramics are used for the development of diverse applications such as cements, macroporous scaffolds and coatings. From this perspective, we present a systematic overview on diverse kinds of magnesium based bioceramics, their processing regimes for different clinical purposes and their behavior both in vitro and in vivo.

Effects of powder-to-liquid ratio on properties of β-tricalcium-phosphate cements modified using high-energy ball-milling

The authors have developed a β-tricalcium-phosphate (β-TCP) powder modified mechano-chemically through the application of a ball-milling process (mβ-TCP). The resulting powder can be used in a calcium-phosphate-cement (CPC). In this study, the effects of the powder-to-liquid ratio (P/L ratio) on the properties of the CPCs were investigated, and an appropriate P/L ratio that would simultaneously improve injectability and strength was clarified. The mβ-TCP cement mixed at a P/L ratio of 2.5 and set in air exhibited sufficient injectability until 20 min after mixing, and strength similar to or higher than that mixed at a P/L ratio of 2.0 and 2.78. Although the mβ-TCP cements set in vivo and in SBF were found to exhibit a lower strength than those set in air, it did have an appropriate setting time and strength for clinical applications. In conclusion, P/L ratio optimization successfully improved the strength of injectable mβ-TCP cement.